Scholars Central

Conference abstractPublished 3 Oct 2016

Targeting triple-negative breast cancer by inhibiting cancer stem-like cell (CSC) expansion

Authors: Guan Chen

Medical College of Wisconsin, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Triple negative breast cancer (TNBC) is highly progressive and lacks established targets for therapeutic intervention. p38g mitogen-activated protein kinase (MAPK) (gene name: MAPK12) is overexpressed in TNBC but how overexpressed p38g contributes to TNBC remains unknown. Here we show that p38g activation promotes TNBC development and progression by stimulating cancer stem-like cell (CSC) expansion and may serve as a novel therapeutic target for TNBC. p38g silencing in TNBC cells inhibits mammosphere formation and reduces levels of key CSC drivers’ expression including Nanog, Oct3/4, and Sox2. Moreover, p38g MAPK-forced expression alone is sufficient to stimulate CSC expansion and to induce malignant transformation with a phenotype resembling to TNBC in vitro and in vivo. Furthermore, p38g depends on its activity to stimulate CSC expansion and breast cancer progression, indicating a therapeutic opportunity by application of its pharmacological inhibitor. Indeed, the non-toxic p38g specific pharmacological inhibitor pirfenidone selectively inhibits TNBC growth in vitro and/or in vivo and significantly decreases CSC population. Mechanistically, p38g stimulates Nanog expression through AP-1 via interaction with c-Jun. These results together demonstrate that p38g drives TNBC development and progression and may be thus a novel therapeutic target by stimulating CSC expansion. Inhibiting p38g activity with pirfenidone may be a novel strategy for the treatment of TNBC

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Guan Chen”